Skip to main content
TipRanks
Go Ultimate75% OFF

Ansell (ANSLF) AI Stock Analysis

20 Followers
ANSLF

Ansell

(Other OTC:ANSLF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Margin ExpansionImproved margins indicate that Ansell is converting revenue into earnings more effectively through better mix, pricing, and productivity. If sustained, this strengthens internal funding capacity and provides resilience against moderate cost pressure across its PPE markets.
Negative Factors
Uneven Revenue TrendA history of uneven revenue growth makes future earnings less predictable and suggests that demand recovery has not yet become consistently broad-based. This can limit operating leverage and make margin progress more dependent on execution and market mix.

Ansell (ANSLF) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%ANSLF-6.24%SPY+11.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$3.05B
Dividend Yield
3.15%
Average Volume (3M)
―
Price to Earnings (P/E)
21.2
Beta (1Y)
0.59
Revenue Growth
6.83%
EPS Growth
109.40%
Country
US
Employees
15,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Ansell Business Overview & Revenue Model

Company Description

Ansell Limited is a global enterprise that conceptualizes, innovates, and produces protective equipment for various industries across numerous regions, including Asia Pacific, Europe, the Middle East, Africa, the Americas, and the Caribbean. The comp...

Ansell Earnings Call Summary

Earnings Call Date:Aug 23, 2026(Q4-2026)|Next Earnings Date:Feb 22, 2027
Earnings Call SentimentPositive

The call presented a clear majority of positive operational and financial outcomes — double-digit EPS growth, higher margins, strong cash conversion, U.S. and Cleanroom-led sales momentum, recurring cost savings (APIP $50M) and improved balance sheet metrics. Management also acknowledged and proactively managed notable headwinds (Middle East cost inflation, U.S. tariffs, commodity volatility, FX hedge losses and non‑cash impairments), and provided a constructive FY'27 EPS guidance range of $1.58–$1.70 with assumptions of continued volume/price momentum and ~$9M FX tailwind. On balance the positives — strong execution, margin expansion, cash generation and concrete operational improvements — outweigh the transient and manageable risks cited.

Positive Updates

Top-line growth and second-half momentum
Adjusted net sales grew 5.7% for FY'26 (ex-FX and product exits). Second-half growth accelerated to 9.2%, driven by improving volume trends.

Negative Updates

Middle East crisis cost volatility and ongoing uncertainty
Middle East conflict caused raw material and cost inflation; management passed costs to customers to offset impacts but emphasized continued uncertainty and the need for flexible pricing going forward.

Company Guidance

Ansell guided adjusted EPS of $1.58–$1.70 for FY27 (FY26 adjusted EPS $1.486), implying ~6.4%–14.4% upside (midpoint ~$1.64, ≈10.3% growth), on assumptions of continued sales momentum from both volume and pricing, focus on higher‑margin markets/brands and ongoing commercial and operational excellence; management also factored in a $9m FX benefit versus FY25. They expect GPADE and margin improvement from mix and productivity, SG&A to be managed around prior‑year growth (~2.7%), lower net capex than FY26 ($48.6m) with targeted strategic investment, continuation of the on‑market buyback program, and a conservative funding profile (net debt/EBITDA target 1.5–2.5x, currently 1.3x) with $752m of cash and undrawn facilities — while noting macro uncertainty.

Ansell Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ANSLF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:RMDAU:RMD84OutperformAUD 51.10B22.0425.14%1.01%1.54%4.43%
AU:NANAU:NAN67NeutralAUD 885.54M50.598.16%―2.59%-13.36%
AU:MVPAU:MVP57NeutralAUD 47.88M75.891.13%―8.99%450.00%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:CSXAU:CSX47NeutralAUD 35.72M-29.22-6.27%―0.29%-148.39%
AU:TRJAU:TRJ44NeutralAUD 51.21M-83.75-0.62%―-3.05%86.01%

* Healthcare Sector Average

Performance Comparison

-60%-40%-20%0%ANSLFAU:NANAU:MVPAU:TRJAU:CSXAU:RMDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ANSLF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ANSLFAnsell Limited21.64-1.44-6.24%
AU:NANNanosonics Limited2.96-1.01-25.44%
AU:MVPMedical Developments International Limited0.42-0.09-16.67%
AU:TRJTrajan Group Holdings Ltd0.34-0.32-48.46%
AU:CSXCleanSpace Holdings Ltd.0.45-0.21-31.82%
AU:RMDResmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh35.50-1.90-5.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.